CN102778567B - 一种双功能肿瘤诊断试剂及方法 - Google Patents
一种双功能肿瘤诊断试剂及方法 Download PDFInfo
- Publication number
- CN102778567B CN102778567B CN201110122433.0A CN201110122433A CN102778567B CN 102778567 B CN102778567 B CN 102778567B CN 201110122433 A CN201110122433 A CN 201110122433A CN 102778567 B CN102778567 B CN 102778567B
- Authority
- CN
- China
- Prior art keywords
- difunctional
- ferritin
- protein shell
- tumor diagnosis
- bionical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 108
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 33
- 238000003745 diagnosis Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 201000011510 cancer Diseases 0.000 claims abstract description 29
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 22
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 21
- 108050000784 Ferritin Proteins 0.000 claims description 108
- 102000008857 Ferritin Human genes 0.000 claims description 105
- 238000008416 Ferritin Methods 0.000 claims description 105
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 108010002084 Apoferritins Proteins 0.000 claims description 15
- 102000000546 Apoferritins Human genes 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 13
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 241000724254 Cowpea chlorotic mottle virus Species 0.000 claims description 6
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 241000219977 Vigna Species 0.000 claims description 4
- 235000010726 Vigna sinensis Nutrition 0.000 claims description 4
- 238000012412 chemical coupling Methods 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 241000206602 Eukaryota Species 0.000 claims description 3
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 229910000420 cerium oxide Inorganic materials 0.000 claims description 3
- 229910001092 metal group alloy Inorganic materials 0.000 claims description 3
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000010970 precious metal Substances 0.000 claims description 3
- 238000001338 self-assembly Methods 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 239000011664 nicotinic acid Substances 0.000 abstract description 2
- 230000002980 postoperative effect Effects 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000011160 research Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 49
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 13
- 239000012188 paraffin wax Substances 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000037976 chronic inflammation Diseases 0.000 description 11
- 230000006020 chronic inflammation Effects 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 239000000975 dye Substances 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 9
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 201000009365 Thymic carcinoma Diseases 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 229910001447 ferric ion Inorganic materials 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 208000017572 squamous cell neoplasm Diseases 0.000 description 5
- 208000008732 thymoma Diseases 0.000 description 5
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000008508 epithelial proliferation Effects 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 3
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000010420 shell particle Substances 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 206010001167 Adenocarcinoma of colon Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 206010004659 Biliary cirrhosis Diseases 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 108010046015 ferritin receptor Proteins 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004018 waxing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010016613 Fibroadenoma of breast Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 201000009966 breast fibroadenosis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 230000024278 histolysis Effects 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
细胞系/商品编号 | 肿瘤类别 | 反应性 |
SMMC-7721/(TCHu 52) | 肝细胞癌 | + |
HT29/(HTB-38) | 结直肠癌 | + |
MDA-MB-231/(HTB-26) | 乳腺癌 | + |
MX-1/(KG038) | 乳腺癌 | - |
A375/(CRL-1619) | 黑色素瘤 | + |
K562/(CCL-243) | 人慢性髓原白血病 | + |
HeLa/(CCL-2) | 宫颈癌 | + |
SKOV3/(HTB-77) | 卵巢癌 | + |
PC-3/(CRL-1435) | 前列腺癌 | + |
U251/(TCHu 58) | 胶质瘤 | + |
U937/(CRL-1593.2) | 淋巴瘤 | + |
Jurkatr/(TIB-152) | 白血病T细胞 | + |
Claims (13)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110122433.0A CN102778567B (zh) | 2011-05-12 | 2011-05-12 | 一种双功能肿瘤诊断试剂及方法 |
EP12782401.9A EP2733490B1 (en) | 2011-05-12 | 2012-05-10 | Bifunctional tumour diagnosis reagent and method therefor |
JP2014509596A JP6117185B2 (ja) | 2011-05-12 | 2012-05-10 | 二機能の腫瘍診断試薬及び方法 |
PCT/CN2012/075291 WO2012152222A1 (zh) | 2011-05-12 | 2012-05-10 | 一种双功能肿瘤诊断试剂及方法 |
US14/117,229 US20150037817A1 (en) | 2011-05-12 | 2012-05-10 | Bifunctional tumor diagnosis reagent and method for tumor diagnosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110122433.0A CN102778567B (zh) | 2011-05-12 | 2011-05-12 | 一种双功能肿瘤诊断试剂及方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102778567A CN102778567A (zh) | 2012-11-14 |
CN102778567B true CN102778567B (zh) | 2015-05-06 |
Family
ID=47123541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110122433.0A Active CN102778567B (zh) | 2011-05-12 | 2011-05-12 | 一种双功能肿瘤诊断试剂及方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150037817A1 (zh) |
EP (1) | EP2733490B1 (zh) |
JP (1) | JP6117185B2 (zh) |
CN (1) | CN102778567B (zh) |
WO (1) | WO2012152222A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103808926B (zh) * | 2014-01-14 | 2016-08-17 | 中国科学院生物物理研究所 | 纳米模拟酶免疫层析检测方法 |
WO2015135597A1 (en) * | 2014-03-12 | 2015-09-17 | Cic Nanogune - Asociación Centro De Investigación Cooperativa En Nanociencias | Uses and methods for delivery to the nucleus |
CN104013599B (zh) * | 2014-05-28 | 2016-11-23 | 中国科学院生物物理研究所 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
JP6979620B2 (ja) * | 2016-05-09 | 2021-12-15 | パナソニックIpマネジメント株式会社 | 発電設備監視システム、発電設備監視方法、及びプログラム |
CN108503704A (zh) * | 2017-02-27 | 2018-09-07 | 昆山新蕴达生物科技有限公司 | 穿越血脑屏障的纳米药物载体 |
CN108969774A (zh) * | 2017-06-05 | 2018-12-11 | 中科蕴达生物科技(北京)有限公司 | 一种诊断动脉粥样硬化不稳定斑块的试剂及方法 |
CN109148067B (zh) * | 2018-07-16 | 2020-09-11 | 中国计量科学研究院 | 表面共价有机框架材料修饰的磁性纳米材料及制备、应用 |
CN110179997B (zh) * | 2018-08-08 | 2020-02-14 | 昆山新蕴达生物科技有限公司 | 一种用于糖尿病治疗的纳米药物载体及其组合药物 |
CN109852666B (zh) * | 2019-01-17 | 2021-01-01 | 中国科学院生物物理研究所 | 一种用于肝癌诊断的特异性靶点及诊断试剂 |
CN111840250B (zh) * | 2019-04-29 | 2023-07-04 | 中国科学院生物物理研究所 | 一种用于恶性脑疟治疗的新型试剂及方法 |
CN112708415B (zh) * | 2020-12-23 | 2023-02-07 | 国家纳米科学中心 | 含铁纳米探针、制备方法及同步辐射用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101037676A (zh) * | 2006-03-13 | 2007-09-19 | 中国科学院生物物理研究所 | 磁性纳米材料的新功能及新用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040028694A1 (en) * | 2002-02-01 | 2004-02-12 | Young Mark J. | Novel nanoparticles and use thereof |
US8217143B2 (en) * | 2006-07-13 | 2012-07-10 | National Institute Of Aerospace Associates | Fabrication of metal nanoshells |
US9302116B2 (en) * | 2007-11-06 | 2016-04-05 | Duke University | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation |
-
2011
- 2011-05-12 CN CN201110122433.0A patent/CN102778567B/zh active Active
-
2012
- 2012-05-10 JP JP2014509596A patent/JP6117185B2/ja active Active
- 2012-05-10 EP EP12782401.9A patent/EP2733490B1/en active Active
- 2012-05-10 US US14/117,229 patent/US20150037817A1/en not_active Abandoned
- 2012-05-10 WO PCT/CN2012/075291 patent/WO2012152222A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101037676A (zh) * | 2006-03-13 | 2007-09-19 | 中国科学院生物物理研究所 | 磁性纳米材料的新功能及新用途 |
Non-Patent Citations (3)
Title |
---|
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1;Li Li et al.;《Proc Natl Acad Sci U S A.》;20100223;第107卷(第8期);3505-3510 * |
Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles;Masaki Uchida et al.;《J. AM. CHEM. SOC.》;20061208;第128卷(第51期);16626-16633 * |
Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas;E. Ryschich et al.;《Eur J Cancer》;20040630;第40卷(第9期);1418-1422 * |
Also Published As
Publication number | Publication date |
---|---|
CN102778567A (zh) | 2012-11-14 |
US20150037817A1 (en) | 2015-02-05 |
JP2014516153A (ja) | 2014-07-07 |
JP6117185B2 (ja) | 2017-04-19 |
EP2733490A1 (en) | 2014-05-21 |
EP2733490B1 (en) | 2017-02-22 |
EP2733490A4 (en) | 2014-12-17 |
WO2012152222A1 (zh) | 2012-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102778567B (zh) | 一种双功能肿瘤诊断试剂及方法 | |
Chu et al. | Labeling tumor cells with fluorescent nanocrystal–aptamer bioconjugates | |
Song et al. | Fluorescent-magnetic-biotargeting multifunctional nanobioprobes for detecting and isolating multiple types of tumor cells | |
Zdobnova et al. | Quantum dots for molecular diagnostics of tumors | |
Zhou et al. | Multifunctional luminescent immuno-magnetic nanoparticles: toward fast, efficient, cell-friendly capture and recovery of circulating tumor cells | |
Luo et al. | Simplified aptamer-based colorimetric method using unmodified gold nanoparticles for the detection of carcinoma embryonic antigen | |
Zhao et al. | State-of-the-art nanotechnologies for the detection, recovery, analysis and elimination of liquid biopsy components in cancer | |
Liu et al. | Persistent luminescence nanophosphor involved near-infrared optical bioimaging for investigation of foodborne probiotics biodistribution in vivo: a proof-of-concept study | |
CN109312293A (zh) | 用于进行磁浮分离的组合物和方法 | |
CN106501239B (zh) | 一种基于聚多巴胺纳米微球的电致化学发光传感器的制备方法 | |
Conde et al. | RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing | |
Elingarami et al. | Surface-engineered magnetic nanoparticles for molecular detection of infectious agents and cancer | |
JP6795813B2 (ja) | がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物 | |
Chen et al. | Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells | |
Zhang et al. | Matter, energy and information network of a graphene-peptide-based fluorescent sensing system for molecular logic computing, detection and imaging of cancer stem cell marker CD133 in cells and tumor tissues | |
CN104707150B (zh) | 肿瘤酶激活的量子点探针及其制备方法与用途 | |
Liu et al. | Rapid visualizing and pathological grading of bladder tumor tissues by simple nanodiagnostics | |
Cui et al. | Fluorescent magnetic nanoprobes for in vivo targeted imaging and hyperthermia therapy of prostate cancer | |
Oghabian et al. | Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI | |
Tang et al. | LHRH-targeting surface-enhanced Raman scattering tags for the rapid detection of circulating tumor cells | |
Sun et al. | Targeting breast cancer cells with a CuInS2/ZnS quantum dot-labeled Ki-67 bioprobe | |
CN104313139A (zh) | 一种单分子细胞检测方法及其应用和单分子细胞检测试剂盒 | |
MX2012000086A (es) | Peptidos derivados de soricidi y metodos para la la deteccion de canceres trpv-6 y suministro de farmaco. | |
Zimina et al. | Biosensors and drug delivery in oncotheranostics using inorganic synthetic and biogenic magnetic nanoparticles | |
Wang et al. | Highly sensitive detection of CTLA‑4‑positive T‑cell subgroups based on nanobody and fluorescent carbon quantum dots |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200131 Address after: 300270 3rd floor, west side of No.5 workshop, no.336, qinger street, Nangang Industrial Zone, Tianjin Economic and Technological Development Zone, Binhai New Area, Tianjin Patentee after: Gil Biotechnology (Tianjin) Co., Ltd. Address before: 100101 No.15 Datun Road, Chaoyang District, Beijing Co-patentee before: INSTITUTE OF GEOLOGY AND GEOPHYSICS, CHINESE ACADEMY OF SCIENCES Patentee before: Institute of Biophysics, Chinese Academy of Sciences |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210226 Address after: 400000 3-3, 3-4, building 5, No.8, Gangcheng East Road, Jiangbei District, Chongqing Patentee after: CHONGQING KANG JU QUAN HONG BIOTECHNOLOGY Co.,Ltd. Address before: 300270 3rd floor, west side of No.5 factory building, no.336, qinger street, Middle District, Nangang Industrial Zone, Tianjin Binhai New Area, Tianjin Patentee before: GL BIO-TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |